vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Third Coast Bancshares, Inc. (TCBX). Click either name above to swap in a different company.
Third Coast Bancshares, Inc. is the larger business by last-quarter revenue ($57.7M vs $44.9M, roughly 1.3× AbCellera Biologics Inc.). Third Coast Bancshares, Inc. runs the higher net margin — 28.4% vs -19.9%, a 48.3% gap on every dollar of revenue. Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 17.5%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Third Coast Bancshares, Inc. is a regional financial holding company headquartered in the U.S. Gulf Coast region. It provides a full suite of commercial and retail banking services including deposit products, business and consumer loans, mortgage services, and wealth management solutions, serving local small and medium-sized enterprises, individual consumers, and community clients across Texas and surrounding areas.
ABCL vs TCBX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $57.7M |
| Net Profit | $-8.9M | $16.4M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | — |
| Net Margin | -19.9% | 28.4% |
| Revenue YoY | 788.4% | — |
| Net Profit YoY | 73.9% | 20.5% |
| EPS (diluted) | $-0.03 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $57.7M | ||
| Q4 25 | $44.9M | $56.5M | ||
| Q3 25 | $9.0M | $54.5M | ||
| Q2 25 | $17.1M | $52.0M | ||
| Q1 25 | $4.2M | $45.9M | ||
| Q4 24 | $5.0M | $46.3M | ||
| Q3 24 | $6.5M | $42.9M | ||
| Q2 24 | $7.3M | $41.7M |
| Q1 26 | — | $16.4M | ||
| Q4 25 | $-8.9M | $17.9M | ||
| Q3 25 | $-57.1M | $18.1M | ||
| Q2 25 | $-34.7M | $16.7M | ||
| Q1 25 | $-45.6M | $13.6M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | $-51.1M | $12.8M | ||
| Q2 24 | $-36.9M | $10.8M |
| Q1 26 | — | — | ||
| Q4 25 | -63.7% | 38.1% | ||
| Q3 25 | -851.8% | 41.9% | ||
| Q2 25 | -290.2% | 40.5% | ||
| Q1 25 | -1479.6% | 37.8% | ||
| Q4 24 | — | 38.7% | ||
| Q3 24 | -1439.4% | 37.9% | ||
| Q2 24 | -1276.2% | 34.1% |
| Q1 26 | — | 28.4% | ||
| Q4 25 | -19.9% | 31.7% | ||
| Q3 25 | -637.8% | 33.1% | ||
| Q2 25 | -203.3% | 32.2% | ||
| Q1 25 | -1077.2% | 29.6% | ||
| Q4 24 | — | 29.7% | ||
| Q3 24 | -785.4% | 29.8% | ||
| Q2 24 | -504.3% | 25.9% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-0.03 | $1.02 | ||
| Q3 25 | $-0.19 | $1.03 | ||
| Q2 25 | $-0.12 | $0.96 | ||
| Q1 25 | $-0.15 | $0.78 | ||
| Q4 24 | — | $0.80 | ||
| Q3 24 | $-0.17 | $0.74 | ||
| Q2 24 | $-0.13 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $650.5M |
| Total Assets | $1.4B | $6.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $128.5M | $175.2M | ||
| Q3 25 | $83.2M | $116.4M | ||
| Q2 25 | $92.4M | $113.1M | ||
| Q1 25 | $159.3M | $219.0M | ||
| Q4 24 | $156.3M | $371.2M | ||
| Q3 24 | $126.6M | $258.2M | ||
| Q2 24 | $148.3M | $241.8M |
| Q1 26 | — | $650.5M | ||
| Q4 25 | $966.9M | $531.0M | ||
| Q3 25 | $964.0M | $513.8M | ||
| Q2 25 | $1.0B | $496.1M | ||
| Q1 25 | $1.0B | $479.8M | ||
| Q4 24 | $1.1B | $460.7M | ||
| Q3 24 | $1.1B | $450.5M | ||
| Q2 24 | $1.1B | $435.0M |
| Q1 26 | — | $6.6B | ||
| Q4 25 | $1.4B | $5.3B | ||
| Q3 25 | $1.4B | $5.1B | ||
| Q2 25 | $1.4B | $4.9B | ||
| Q1 25 | $1.3B | $4.9B | ||
| Q4 24 | $1.4B | $4.9B | ||
| Q3 24 | $1.4B | $4.6B | ||
| Q2 24 | $1.4B | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | — |
| Free Cash FlowOCF − Capex | $-44.6M | — |
| FCF MarginFCF / Revenue | -99.4% | — |
| Capex IntensityCapex / Revenue | 21.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-34.7M | $50.8M | ||
| Q3 25 | $-52.6M | $20.7M | ||
| Q2 25 | $-32.4M | $13.9M | ||
| Q1 25 | $-11.6M | $10.5M | ||
| Q4 24 | $-108.6M | $35.1M | ||
| Q3 24 | $-28.9M | $22.0M | ||
| Q2 24 | $-30.0M | $7.3M |
| Q1 26 | — | — | ||
| Q4 25 | $-44.6M | — | ||
| Q3 25 | $-61.5M | — | ||
| Q2 25 | $-45.8M | — | ||
| Q1 25 | $-22.2M | — | ||
| Q4 24 | $-187.0M | $33.4M | ||
| Q3 24 | $-47.4M | — | ||
| Q2 24 | $-50.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -99.4% | — | ||
| Q3 25 | -687.0% | — | ||
| Q2 25 | -267.9% | — | ||
| Q1 25 | -524.0% | — | ||
| Q4 24 | -3702.8% | 72.1% | ||
| Q3 24 | -728.4% | — | ||
| Q2 24 | -683.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 21.9% | — | ||
| Q3 25 | 99.7% | — | ||
| Q2 25 | 78.2% | — | ||
| Q1 25 | 251.1% | — | ||
| Q4 24 | 1552.7% | 3.8% | ||
| Q3 24 | 284.6% | — | ||
| Q2 24 | 274.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.84× | ||
| Q3 25 | — | 1.15× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | 2.56× | ||
| Q3 24 | — | 1.72× | ||
| Q2 24 | — | 0.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABCL
Segment breakdown not available.
TCBX
| Net Interest Income | $53.6M | 93% |
| Noninterest Income | $4.0M | 7% |
